G-Quadruplex Stabilizing Compounds for Anti-Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that stabilize G-quadruplex DNA and RNA have limited selectivity and are challenging to synthesize in commercially viable quantities, hindering their development as effective anti-cancer agents.
Innovation Solution
Development of novel compounds of formula (I) that stabilize G-quadruplex DNA and RNA, possessing anti-cancer properties, which can be prepared using commercially viable starting materials and processes, with specific structural features allowing for improved binding affinity and therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to stabilize G-quadruplex DNA with high selectivity, then binding affinity improves, but synthetic complexity increases
Solution Approach 1:
The compound is divided into distinct functional modules: a planar aromatic core (triazolo[4,5-d]pyrimidinone or pyrimido[5,4-d]pyrimidinone) for G-quadruplex binding, and substituents (R1-R6) that can be independently optimized for selectivity and pharmacological properties. This modular structure allows systematic optimization of binding affinity while maintaining synthetic accessibility through standardized coupling reactions.
Solution Approach 2:
The patent employs systematic variation of substituent parameters (R1-R6 groups including halogens, alkyls, aryls, and heteroaryl groups) to optimize the balance between binding affinity and synthetic complexity. By changing these molecular parameters in a controlled manner, the invention achieves high selectivity for G-quadruplex DNA while maintaining feasibility of commercial-scale synthesis.
2Reliability
If compounds are developed with improved binding affinity, then therapeutic efficacy improves, but manufacturing cost increases
Solution Approach 1:
The core heterocyclic structure serves multiple functions: it provides the planar aromatic surface for G-quadruplex stacking interactions, offers positions for diverse substituent attachment to achieve selectivity, and maintains structural rigidity for optimal binding geometry. This multi-functionality of the core structure reduces the need for complex auxiliary groups, thereby lowering manufacturing costs while maintaining therapeutic efficacy.
Solution Approach 2:
The patent utilizes commercially available starting materials and standard organic synthesis building blocks for the R1-R6 substituents. These simple, readily accessible components can be incorporated through efficient coupling reactions, enabling cost-effective manufacturing at scale while achieving the desired binding affinity and therapeutic effect.
3Reliability
If compounds are synthesized with high selectivity for G-quadruplex, then therapeutic potential improves, but production yield decreases
Solution Approach 1:
The patent designs the molecular structure with pre-positioned functional groups and substitution patterns that inherently guide selective binding to G-quadruplex DNA. The predetermined arrangement of R1-R6 substituents on the core structure ensures high selectivity is built into the molecule itself, eliminating the need for complex post-synthesis purification steps and thereby maintaining high production yields.
Data Source
AI summary
The invention provides compounds of formula (I) wherein u, d, v, m, n, R1, W, X, Y, and Z have any values defined herein, as well as salts thereof. The compounds have activity as anti-proliferative agents.